Serotonin Uptake Inhibitors - Administration & dosage
Research News and Information

Sunday, November 22, 2009

[Benzodiazepine reduction does not imply an increased consumption of antidepressants. A survey of two medical practices]

3 Oct 2009 INTRODUCTION: The consumption of benzodiazepines (BZ) and cyclopyrrolones (CP) has attracted great interest in recent years due to the serious side-effects associated with these drugs. Two medical practices introduced a more restrictive approach to ... Read more...

The synergistic interaction between morphine and maprotiline after intrathecal injection in rats.

29 Sep 2009 BACKGROUND: Antidepressant drugs act as potent inhibitors of norepinephrine and/or serotonin reuptake and are widely used with opioids for the treatment of chronic pain. The mechanism of this increased analgesic action is unclear. We compared the ... Read more...

Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors.

26 Sep 2009 OBJECTIVE: This study investigated neonatal S100B levels as a biomarker of prenatal selective serotonin reuptake inhibitor (SSRI) exposure. METHODS: Maternal (delivery; N = 53) and neonatal (cord; N = 52) serum S100B levels were compared between ... Read more...

Latest indexed articles for 'Serotonin Uptake Inhibitors - Administration & dosage'

These are the very latest articles for this heading:

• [Benzodiazepine reduction does not imply an increased consumption of antidepressants. A survey of two medical practices] 3 Oct 2009
• The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. 29 Sep 2009
• Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. 26 Sep 2009
• [Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine] 30 Jul 2009
• Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. 30 Jul 2009
• Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. 30 Jul 2009
• Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. 30 Jul 2009
• Use of a selective serotonin reuptake inhibitor for treatment of episodes of hypertonia and kyphosis in a young adult Scottish Terrier. 13 Jul 2009
• Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. 29 Jun 2009
• Clinical and ECG effects of escitalopram overdose. 23 Jun 2009
• Behavioral and psychological symptoms of dementia and medical treatment. 30 May 2009
• Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. 30 May 2009
• Self-inflicted non-healing genital ulcer: a rare form of factitious disorder. 30 May 2009
• Effect of a single dose of citalopram on amygdala response to emotional faces. 30 May 2009
• A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. 3 May 2009
• Fluoxetine potentiates the effects of corticotropin-releasing factor on locomotor activity and serotonergic systems in the roughskin newt, Taricha granulosa. May 2009
• Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. 29 Apr 2009
• Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. 29 Apr 2009
• Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline. 29 Apr 2009
• Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin/norepinephrine reuptake inhibitors. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Serotonin Uptake Inhibitors'

Definition: Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behavior, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the ADRENERGIC UPTAKE INHIBITORS also inhibit serotonin uptake; they are not included here.

Registry Number: 0

Descriptor UI: D017367

Alternative terms: Serotonin Uptake Inhibitors; Uptake Inhibitors, 5-HT; Uptake Inhibitors, 5 HT; 5-HT Uptake Inhibitors; 5 HT Uptake Inhibitors; Inhibitors, 5-Hydroxytryptamine Uptake; Inhibitors, 5 Hydroxytryptamine Uptake; Uptake Inhibitors, 5-Hydroxytryptamine; Uptake Inhibitors, 5 Hydroxytryptamine; Inhibitors, Serotonin Reuptake; Reuptake Inhibitors, Serotonin; Serotonin Reuptake Inhibitors; Inhibitors, Serotonin Uptake; Uptake Inhibitors, Serotonin; Inhibitors, 5-HT Uptake; Inhibitors, 5 HT Uptake; 5-Hydroxytryptamine Uptake Inhibitors; 5 Hydroxytryptamine Uptake Inhibitors;

Related Mesh Headings: Antidepressive Agents, Second-Generation; Adrenergic Uptake Inhibitors;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.625.600.850; D27.505.519.625.850.900; D27.505.696.577.600.850; D27.505.696.577.850.900;

History Note: 93

Technical Notes: GEN or unspecified; prefer specifics; do not confuse with SEROTONIN ANTAGONISTS; DF: SEROTONIN UPTAKE INHIB